title: Ganciclovir pharmacokinetics during renal impairment.
abstract: Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.
authors.affiliation: Division of Cardiothoracic Transplantation and Research, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minnesota.
authors.forename: K D
authors.initials: KD
authors.lastname: Lake
authors.forename: C V
authors.initials: CV
authors.lastname: Fletcher
authors.forename: K R
authors.initials: KR
authors.lastname: Love
authors.forename: D C
authors.initials: DC
authors.lastname: Brown
authors.forename: L D
authors.initials: LD
authors.lastname: Joyce
authors.forename: M R
authors.initials: MR
authors.lastname: Pritzker
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000328:Adult; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D005260:Female; D015774:Ganciclovir; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D006435:Renal Dialysis
chemical_list: D015774:Ganciclovir; D000212:Acyclovir